Cancer drug olaparib may cause folate deficiency, small study finds
NCT ID NCT04024254
First seen Nov 21, 2025 · Last updated Jun 07, 2026 · Updated 30 times
Summary
This study checked if the cancer drug olaparib causes a lack of folic acid (folate deficiency) in patients with advanced ovarian or breast cancer. Ten postmenopausal women were followed to see how many developed low folate levels and how quickly it happened. The goal was to understand a possible side effect of the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.